Market Intelligence

Access the latest earnings reports, market analysis, hot topics, and individual stock insights

Report Categories

View All

Recent Articles

View All
South Koreas KOSPI Reaches Record High as Asian Markets Eye USIran Talks USChina Trade Tensions Persist at APEC Three Signs of Lingering Differences NVIDIA Corporation Reports Record Quarterly Revenue of 816 Billion in Fiscal Q1 2027 Inside the Pokmon Card Boom Nostalgia Speculation and MillionDollar Sales The Fed May Have Fewer Justifications for Rate Cuts CNBC Analysis Suggests Joby Aviation Q1 2026 Earnings EPS Surprise Beats Estimates Amid Certification Progress DUOL Q1 2026 Earnings EPS Beats Estimates by 164 Stock Edges Higher SLF Q1 2026 Earnings Slight EPS Miss Amid Steady Operations Ita Unibanco ITUB Q1 2026 Earnings EPS Misses Estimates as Provisions Weigh on Results Shares Slip 225 Kairos Pharma Ltd KAPA Q1 2026 Earnings EPS Misses Estimates as Stock Declines 411 GMEX Robotics Slides 262 as Shares Test Key Support at 177 Offerpad Solutions OPAD Edges Lower Testing Key Support at 066 Red Cat Holdings RCAT Surges Over 4 Drone Stock Tests Key Resistance at 988 FB Financial Corporation FBK Holds Steady Near Midpoint as Trading Volume Remains Subdued US Bank Analysis How the Job Market Shapes Economic Trends Bitcoin Surges Past 77000 as Iran Deal Optimism and Nasdaq Crypto Options Development Boost Sentiment Air India Slashes Domestic Flights by 22 Amid Rising Fuel Costs Strive Asset Management Increases Bitcoin Holdings to 16500 Tokens Signaling Institutional Confidence Everest Group EG Q1 2026 Earnings Strong EPS Beat Amid Stable Underwriting Conditions Upstream Bio UPB Q1 2026 Earnings NarrowerThanExpected Loss Amid No Revenue Stock Edges Lower VERI Q1 2026 Earnings EPS Misses Estimates Stock Falls Over 6 Rhinebeck Bancorp Inc RBKB Q1 2026 Earnings Solid EPS of 020 Reinforces Steady Performance Valens Semiconductor VLN Q1 2026 Earnings EPS Beat Drives 5 Stock Surge Amid Revenue Data Gaps Ernexa Therapeutics ERNA Q3 2023 Earnings Deepening Losses and ClinicalPhase Uncertainty Weigh on Shares